Comparative Pharmacology
Head-to-head clinical analysis: HARMONYL versus RAPLON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HARMONYL versus RAPLON.
HARMONYL vs RAPLON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Harmonyl is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and blood pressure.
RAPLON (levosimendan) is a calcium sensitizer that increases myocardial contractility by sensitizing troponin C to calcium, and it also opens ATP-sensitive potassium channels, causing vasodilation.
25 mg orally once daily, taken with food. Maximum dose: 50 mg once daily.
0.2 mg/kg IV bolus over 30 seconds; may repeat once if necessary after 15 minutes.
None Documented
None Documented
Terminal half-life: 12–18 hours (mean 15 h); extends to 24–30 h in hepatic impairment
Terminal elimination half-life is approximately 1.5-2.5 hours in patients with normal renal function; prolonged in renal impairment (up to 6-8 hours in end-stage renal disease).
Renal: 70% as unchanged drug; Biliary/fecal: 20% as metabolites; 10% other
Primarily renal excretion of unchanged drug (approximately 80-90% of administered dose within 24 hours); minor biliary/fecal elimination (less than 10%).
Category C
Category C
Antihypertensive
Antihypertensive